J Korean Diabetes.  2021 Dec;22(4):244-249. 10.4093/jkd.2021.22.4.244.

2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea

• Ko SH

• KMID: 2526207
• DOI: http://doi.org/10.4093/jkd.2021.22.4.244

Abstract

The Committee of Clinical Practice Guidelines of the Korean Diabetes Association (KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and prediabetes and published the seventh edition in May 2021. We performed a comprehensive systematic review of recent clinical trials and evidence from real-world practice among the Korean population. The guidelines are intended for use at sites across the country by all healthcare providers (including physicians, diabetes experts, and certified diabetes educators) who treat diabetes. The recommendations for screening and antihyperglycemic agents have been revised and updated. Continuous glucose monitoring with insulin pump use and screening and treatment for non-alcoholic fatty liver disease were added in the type 2 diabetes sections. The KDA recommends active vaccination for COVID-19 in patients with diabetes. An abridgement that contains practical information for patient education and systematic clinic management was published separately.

Keyword

Clinical practice guidelines; Diabetes

Reference

1.Jung CH., Son JW., Kang S., Kim WJ., Kim HS., Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of cur-rent status. Diabetes Metab J. 2021. 45:1–10.

2.Korean Diabetes Association. Diabetes fact sheet in Korea. Seoul: Korean Diabetes Association;2020.

3.Korean Diabetes Association. Clinical practice guidelines for diabetes. Available from:. http://kdaguideline.com. (updated 2021 Dec 1).

4.Lee JH., Chon S., Cha SA., Lim SY., Kim KR., Yun JS, et al. Korean Diabetes Prevention Study Investigators. Impaired fasting glucose levels in overweight or obese subjects for screening of type 2 diabetes in Korea. Korean J Intern Med. 2021. 36:382–91.

5.Rhee SY., Chon S., Ahn KJ., Woo JT. Korean Diabetes Prevention Study Investigators. Hospital-based Korean Diabetes Prevention Study: a prospective, multi-center, randomized, open-label controlled study. Diabetes Metab J. 2019. 43:49–58.

6.Lee JH., Lim SY., Cha SA., Han CJ., Jung AR., Kim KR, et al. Short-term effects of the internet-based Korea Diabetes Prevention Study: 6-month results of a community-based randomized controlled trial. Diabetes Metab J 2021. DOI: doi: 10.4093/dmj.2020.0225. [Epub ahead of print].

7.Holman RR., Paul SK., Bethel MA., Matthews DR., Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. 359:1577–89.

8.Writing Group for the DCCT/EDIC Research Group. Orchard TJ., Nathan DM., Zinman B., Cleary P., Brillon D, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015. 313:45–53.

9.Matthews DR., Paldánius PM., Proot P., Chiang Y., Stumvoll M., Del Prato S. VERIFY study group. Glycaemic durabil-ity of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019. 394:1519–29.

10.Zinman B., Wanner C., Lachin JM., Fitchett D., Bluhmki E., Hantel S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015. 373:2117–28.

11.Wiviott SD., Raz I., Bonaca MP., Mosenzon O., Kato ET., Cahn A, et al. DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019. 380:347–57.

12.Marso SP., Daniels GH., Brown-Frandsen K., Kristensen P., Mann JF., Nauck MA, et al. LEADER Steering Committee. LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016. 375:311–22.

13.Packer M., Anker SD., Butler J., Filippatos G., Pocock SJ., Carson P, et al. EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. 383:1413–24.

14.Wanner Ch., Inzucchi SE., Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016. 375:1801–2.

15.Heerspink HJL., Stefánsson BV., Correa-Rotter R., Chertow GM., Greene T., Hou FF, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020. 383:1436–46.

16.Schectman JM., Nadkarni MM., Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002. 25:1015–21.

17.Cohen R., Le Roux CW., Junqueira S., Ribeiro RA., Luque A. Roux-en-Y gastric bypass in type 2 diabetes patients with mild obesity: a systematic review and meta-analysis. Obes Surg. 2017. 27:2733–9.

18.Yeo D., Yeo C., Low TY., Ahmed S., Phua S., Oo AM, et al. Outcomes after metabolic surgery in Asians- a meta-anal-ysis. Obes Surg. 2019. 29:114–26.

19.SPRINT Research Group. Wright JT Jr., Williamson JD., Whelton PK., Snyder JK., Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015. 373:2103–16.

20.Buckley LF., Dixon DL., Wohlford GF 4th., Wijesinghe DS., Baker WL., Van Tassell BW. Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP. Diabetes Care. 2017. 40:1733–8.

21.Bangalore S., Fakheri R., Toklu B., Messerli FH. Diabetes mellitus as a compelling indication for use of renin angio-tensin system blockers: systematic review and meta-analy-sis of randomized trials. BMJ. 2016. 352:i438.

22.Arnold SV., Bhatt DL., Barsness GW., Beatty AL., Deedwa-nia PC., Inzucchi SE, et al. American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020. 141:e779–806.

23.Brugts JJ., Yetgin T., Hoeks SE., Gotto AM., Shepherd J., Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009. 338:b2376.

24.Sabatine MS., Giugliano RP., Keech AC., Honarpour N., Wiviott SD., Murphy SA, et al. FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017. 376:1713–22.

25.Schwartz GG., Steg PG., Szarek M., Bhatt DL., Bittner VA., Diaz R, et al. ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018. 379:2097–107.

26.Chalasani N., Younossi Z., Lavine JE., Charlton M., Cusi K., Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018. 67:328–57.

27.Heinemann L., Freckmann G., Ehrmann D., Faber-Heine-mann G., Guerra S., Waldenmaier D, et al. Real-time Continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018. 391:1367–77.

28.Battelino T., Phillip M., Bratina N., Nimri R., Oskarsson P., Bolinder J. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care. 2011. 34:795–800.

29.Seyed Ahmadi S., Westman K., Pivodic A., Ólafsdóttir AF., Dahlqvist S., Hirsch IB, et al. The association between HbA1c and time in hypoglycemia during CGM and self-monitoring of blood glucose in people with type 1 diabetes and multiple daily insulin injections: a randomized clinical trial (GOLD-4). Diabetes Care. 2020. 43:2017–24.

30.Beck RW., Riddlesworth TD., Ruedy K., Ahmann A., Haller S., Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017. 167:365–74.

31.Yeh HC., Brown TT., Maruthur N., Ranasinghe P., Berger Z., Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012. 157:336–47.

32.Forlenza GP., Li Z., Buckingham BA., Pinsker JE., Cengiz E., Wadwa RP, et al. Predictive low-glucose suspend re-duces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: results of the PROLOG trial. Diabetes Care. 2018. 41:2155–61.

33.Bergenstal RM., Tamborlane WV., Ahmann A., Buse JB., Dailey G., Davis SN, et al. Effectiveness of sensor-aug-mented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010. 363:311–20.

34.DAFNE Study Group. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. BMJ. 2002. 325:746.

35.Little SA., Speight J., Leelarathna L., Walkinshaw E., Tan HK., Bowes A, et al. Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: two-year follow-up in the HypoCOMPaSS randomized clinical trial. Diabetes Care. 2018. 41:1600–7.

36.Noh J., Chang HH., Jeong IK., Yoon KH. Coronavirus disease 2019 and diabetes: the epidemic and the Korean Diabetes Association perspective. Diabetes Metab J. 2020. 44:372–81.